Xencor price target lowered to $27 from $29 at Truist
Truist lowered the firm's price target on Xencor to $27 from $29 and keeps a Buy rating on the shares as part of a broader research note updating the firm's models and previewing Q2 earnings in Biotech. The firm is anticipating a rebound from a traditionally softer start to the year, with strength in Q2 prints for comm